Genetek Lifesciences Pvt. Ltd. announced its participation in CPHI Frankfurt 2025, one of the world’s most prestigious pharmaceutical exhibitions. Scheduled for September, the event will bring together leading companies, innovators, and decision-makers from across the pharmaceutical industry.

CPHI is widely recognized as the premier platform for global pharma networking, knowledge exchange, and business development. It serves as a convergence point for manufacturers, suppliers, regulators, and healthcare professionals, offering opportunities to explore collaborations, emerging technologies, and evolving market trends.

For Genetek Lifesciences, participation underscores the company’s commitment to strengthening its international influence. Over the years, the company has established itself as a trusted partner in contrast media, critical care injectables, and probiotics backed by regulatory approvals and compliance with global quality standards. Attending CPHI Frankfurt highlights Genetek’s dedication to innovation, regulatory excellence, and sustainable growth in the competitive pharmaceutical landscape.

Company representatives will be engaging with global partners to showcase Genetek’s manufacturing capabilities, product portfolio, and expanding international presence. The event will also provide a platform to highlight the company’s expertise in delivering high-quality formulations tailored for diverse healthcare markets.

By joining CPHI Frankfurt, Genetek Lifesciences reinforces its vision of becoming a key global contributor to accessible and reliable healthcare solutions, reflecting both its reputation as a reliable manufacturer and its ambition to play a leading role in shaping the future of the pharmaceutical industry.